⬆️
What a moment at #ESMO26! 👏 A standing ovation for DeLLphi-305, and how fitting to see attrition take the Presidential Symposium stage! 🎯
Remarkable survival results deserve celebration. Dr. Liu's discussion added an equally important perspective: only 37% of patients in the LALUCA registry received second-line therapy.
This is why I brought real-world attrition into my post on chemotherapy-free strategies in metastatic CRC and PDAC. It matters enormously.
And that's precisely where therapeutic trifecta convergence matters: activity, tolerability and combinability, working in concert to shape the choreography of treatment, preserve future therapeutic opportunities, and keep the patient at the center of it all.
@StephenVLiu @Alfdoc2 @ArndtVogel @fred_hirsch @drgandara
30 views · 0 likes · 0 reposts · 0 replies
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org🚨🔥 ABSOLUTELY STUNNING! DeLLphi-305 at #ESMO26! @sands_jacob presents remarkable phase III results in ES-SCLC! 💥 Tarlatamab + durvalumab vs durvalumab maintenance 🔥 Median OS: 21.1 vs 12.7 months 🔥 HR 0.42 (95% CI 0.32–0.54), p<0.001 🔥 12-month OS: 79% vs 53% 58% reduction in the hazard of death! These are extraordinary results in a disease where meaningful survival advances have been so difficult to achieve. 👏 Congratulations and I welcome A new benchmark for ES-SCLC maintenance therapy #ESMOAmbassadors #ESMO26 #SCLC #LungCancer #DeLLphi305在 X 查看被引用的帖子
Source: CrozrX · x.com